Total Payments
$241,089
2024 Payments
$42,707
Companies
24
Transactions
343
Medicare Patients
904
Medicare Billing
$103,284
Payment Breakdown by Category
Consulting$100,571 (41.7%)
Other$61,813 (25.6%)
Research$54,855 (22.8%)
Travel$12,599 (5.2%)
Food & Beverage$11,209 (4.6%)
Education$41.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $100,571 | 21 | 41.7% |
| Unspecified | $54,855 | 82 | 22.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,438 | 10 | 13.9% |
| Honoraria | $21,375 | 7 | 8.9% |
| Travel and Lodging | $12,599 | 38 | 5.2% |
| Food and Beverage | $11,209 | 176 | 4.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,000 | 3 | 2.9% |
| Education | $41.76 | 6 | 0.0% |
Payments by Type
General
$186,234
261 transactions
Research
$54,855
82 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $107,549 | 141 | $0 (2024) |
| Allergan, Inc. | $44,932 | 43 | $0 (2022) |
| DERMIRA, INC. | $35,897 | 29 | $0 (2020) |
| Galderma Laboratories, L.P. | $28,214 | 35 | $0 (2023) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $9,295 | 33 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $8,016 | 9 | $0 (2019) |
| Incyte Corporation | $2,851 | 3 | $0 (2023) |
| Merz Pharmaceuticals GmbH | $1,654 | 19 | $0 (2017) |
| Solta Medical, a division of Bausch Health US, LLC | $608.96 | 6 | $0 (2020) |
| MERZ NORTH AMERICA, INC. | $279.06 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,707 | 63 | ABBVIE INC. ($41,605) |
| 2023 | $44,161 | 61 | ABBVIE INC. ($43,548) |
| 2022 | $30,852 | 55 | ABBVIE INC. ($22,271) |
| 2021 | $3,390 | 9 | Galderma Laboratories, L.P. ($3,049) |
| 2020 | $9,872 | 15 | Galderma Laboratories, L.P. ($6,442) |
| 2019 | $53,773 | 58 | DERMIRA, INC. ($35,381) |
| 2018 | $10,482 | 25 | Galderma Laboratories, L.P. ($9,412) |
| 2017 | $45,851 | 57 | Allergan Inc. ($36,499) |
All Payment Transactions
343 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $117.31 | General |
| Category: Inflammation & Immunology | ||||||
| 10/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $84.96 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DERMATOLOGY | ||||||
| 09/10/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $10,800.00 | General |
| 09/06/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 08/27/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $94.66 | General |
| Category: Immunology | ||||||
| 08/23/2024 | ABBVIE INC. | BOTOX (Biological) | — | Cash or cash equivalent | $18,400.00 | Research |
| Study: A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants • Category: FACIAL AESTHETICS | ||||||
| 08/17/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $797.79 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/17/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $153.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/16/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $219.55 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/16/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $160.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 07/18/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: FACIAL AESTHETICS | ||||||
| 05/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 04/27/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $495.97 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/27/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $110.59 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/26/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $361.53 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/26/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $145.00 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/26/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $111.18 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 04/26/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $103.63 | General |
| Category: FACIAL AESTHETICS | ||||||
| 04/23/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $111.62 | General |
| Category: Inflammation | ||||||
| 04/06/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $505.20 | General |
| 04/06/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $234.74 | General |
| 04/06/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $85.92 | General |
| 04/06/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $32.94 | General |
| 04/06/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $27.13 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants | AbbVie Inc. | $26,707 | 34 |
| A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants | ABBVIE INC. | $18,400 | 1 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $5,339 | 19 |
| Validation of the Lateral Canthal Lines Severity Scale and Forehead Lines Severity Scale | ABBVIE INC. | $2,694 | 18 |
| MMP Scale Validation Study | ABBVIE INC. | $1,714 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 9 | 190 | 337 | $49,587 | $23,198 |
| 2021 | 8 | 356 | 723 | $98,373 | $45,398 |
| 2020 | 9 | 358 | 734 | $82,529 | $34,688 |
Total Patients
904
Total Services
1,794
Medicare Billing
$103,284
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 15 | 25 | $15,000 | $7,731 | 51.5% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 12 | 38 | $4,826 | $3,616 | 74.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 52 | $6,448 | $3,305 | 51.2% |
| 96573 | Application of light by qualified health care professional to destroy precancer skin growth | Office | 2022 | 14 | 21 | $7,812 | $3,059 | 39.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 19 | $2,850 | $1,540 | 54.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 15 | 15 | $2,280 | $1,259 | 55.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 35 | 37 | $4,366 | $1,227 | 28.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 14 | 15 | $2,325 | $1,008 | 43.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 26 | 115 | $3,680 | $452.72 | 12.3% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2021 | 24 | 49 | $29,400 | $15,497 | 52.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 96 | 130 | $15,365 | $8,678 | 56.5% |
| 96573 | Application of light and light-sensitive drugs to aid destruction of premalignant skin growths, per day | Office | 2021 | 23 | 45 | $16,740 | $6,905 | 41.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 45 | $6,805 | $4,239 | 62.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 63 | 83 | $9,794 | $3,509 | 35.8% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 28 | 30 | $4,560 | $2,543 | 55.8% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 35 | 39 | $6,045 | $2,543 | 42.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 50 | 302 | $9,664 | $1,484 | 15.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2020 | 26 | 36 | $21,600 | $10,482 | 48.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 100 | 150 | $13,950 | $8,121 | 58.2% |
| 96573 | Application of light and light-sensitive drugs to aid destruction of premalignant skin growths, per day | Office | 2020 | 24 | 33 | $12,276 | $4,295 | 35.0% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 37 | 47 | $7,285 | $3,321 | 45.6% |
| 17000 | Destruction of skin growth | Office | 2020 | 63 | 84 | $9,912 | $3,144 | 31.7% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 20 | 22 | $3,344 | $1,632 | 48.8% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 51 | 321 | $10,272 | $1,436 | 14.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 16 | $2,240 | $1,412 | 63.0% |
About Dee Glaser
Dee Glaser is a Dermatology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962429936.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dee Glaser has received a total of $241,089 in payments from pharmaceutical and medical device companies, with $42,707 received in 2024. These payments were reported across 343 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($100,571).
As a Medicare-enrolled provider, Glaser has provided services to 904 Medicare beneficiaries, totaling 1,794 services with total Medicare billing of $103,284. Data is available for 3 years (2020–2022), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Saint Louis, MO
- Active Since 07/16/2006
- Last Updated 03/11/2021
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1962429936
Products in Payments
- BOTOX (Biological) $73,168
- QBREXZA (Drug) $35,119
- KYBELLA (Biological) $15,381
- ALTRENO (Drug) $8,150
- SKYRIZI (Biological) $2,694
- Xeomin (Biological) $1,933
- ARAZLO (Drug) $314.36
- CIBINQO (Drug) $277.16
- DUOBRII (Drug) $265.00
- VTAMA (Drug) $248.96
- LIBTAYO (Biological) $228.31
- JUBLIA EFINACONAZOLE (Drug) $228.16
- SILIQ (Drug) $203.15
- JUBLIA (Drug) $195.02
- Cabtreo (Drug) $166.71
- Otezla (Drug) $166.62
- Humira (Biological) $124.24
- RINVOQ (Biological) $122.77
- AMELUZ (Drug) $118.79
- Sotyktu (Drug) $94.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Saint Louis
Elaine Siegfried, Md, MD
Dermatology — Payments: $1.1M
Dermatology $1.1M
Dr. Craig Leonardi, M.d, M.D
Dermatology — Payments: $1.0M
Dermatology $1.0M
Dr. Brian Kim, Md, MD
Dermatology — Payments: $760,788
Dermatology $760,788
Dr. Mary Noel George, Md, MD
Dermatology — Payments: $498,600
Dermatology $498,600
Jeffrey Reed, Md, MD
Dermatology — Payments: $188,305
Dermatology $188,305
Dr. Milan Anadkat, Md, MD
Dermatology — Payments: $155,718
Dermatology $155,718